stockrowPelthos Therapeutics Inc.
PTHS Healthcare Biotechnology
Pelthos Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.8 million.
- EPS
- −23.1%
- Free cash flow
- −1,615.0%
- Total debt
- +2,692.8%
Quarter to June 2026, against a year earlier
Follow PTHS
Alert me
Pelthos Therapeutics Inc. (PTHS) Altman Z-score
Pelthos Therapeutics Inc.'s Altman Z-score for fiscal 2025 is −0.75, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.75 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.21 | — | 0.25 | |
| Retained earnings / total assets | (0.50) | — | −0.70 | |
| EBIT / total assets | (0.25) | — | −0.82 | |
| Market value of equity / total liabilities | 0.64 | — | 0.38 | |
| Sales / total assets | 0.13 | — | 0.13 | |
| Altman Z-score | Distress zone | −0.75 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.47 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GRCE Grace Therapeutics, Inc. compare | 3.3× |
| IBO Impact Biomedical Inc. compare | 0.3× |
| ELTX Elicio Therapeutics, Inc. compare | 0.1× |
| PTHS Pelthos Therapeutics Inc. | −0.8× |
| VERU Veru Inc. compare | −5.8× |
| GRDX GridAI Technologies Corp. compare | −6.6× |
| ALDX Aldeyra Therapeutics, Inc. compare | — |
| TVGN Tevogen Inc. compare | — |
| LIANY LianBio Sponsored ADR compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets